<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091143</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000383908</org_study_id>
    <secondary_id>PPMC-IRB-02-99</secondary_id>
    <secondary_id>NCI-6361</secondary_id>
    <nct_id>NCT00091143</nct_id>
  </id_info>
  <brief_title>Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma</brief_title>
  <official_title>A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Cancer Center, Earle A. Chiles Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Vaccines made from peptides may make&#xD;
      the body build an immune response to kill tumor cells. Infusions of a person's white blood&#xD;
      cells may be able to replace immune cells that were destroyed by chemotherapy. Combining&#xD;
      fludarabine with vaccine therapy and white blood cell infusions may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying the side effects of giving vaccine therapy&#xD;
      together with fludarabine and white blood cell infusions and to see how well it works in&#xD;
      treating patients with unresectable or metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity and immune effects of vaccination comprising modified gp100&#xD;
           peptide (gp100:209-217[210M]), Montanide ISA-51, and keyhole limpet hemocyanin followed&#xD;
           by peripheral blood mononuclear cell reinfusion after treatment-induced lymphopenia with&#xD;
           fludarabine in patients with unresectable or metastatic melanoma.&#xD;
&#xD;
        -  Determine the induction of antigen-specific T-cell responses in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the kinetics and duration of immune response in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Compare the immunologic effects of this regimen in these patients with historical&#xD;
           results.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare 2 different dosing schedules of fludarabine, in terms of induction of&#xD;
           lymphopenia and granulocytopenia and on the induction of a specific immune response to&#xD;
           this vaccine, in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, randomized study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      Within 2 weeks before the start of fludarabine, all patients undergo leukapheresis over 4-6&#xD;
      hours for the collection of peripheral blood mononuclear cells (PBMCs).&#xD;
&#xD;
        -  Arm I: Patients receive fludarabine IV over 30 minutes on days 1-5.&#xD;
&#xD;
        -  Arm II: Patients receive fludarabine as in arm I on days 1, 3, and 5. In both arms,&#xD;
           patients receive autologous PBMCs IV over approximately 30 minutes on day 8 and&#xD;
           vaccination comprising gp100:209-217(210M) peptide, Montanide ISA-51, and keyhole limpet&#xD;
           hemocyanin subcutaneously on days 8, 22, 36, 50, and 64. Patients with stable or&#xD;
           responding disease continue to receive vaccination on day 78 and then every 28-31 days&#xD;
           for up to 1 year.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients (10 per treatment arm) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity by clinical and laboratory observation at 1 month</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Antigen-specific T-cell responses by tetramer analysis, ELISPOT, and cytokine flow cytometry periodically</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare 2 different dosing schedules of fludarabine in terms of lymphocyte recovery using a complete blood count periodically</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression by standard imaging at study completion</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>keyhole limpet hemocyanin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant melanoma&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
          -  Received at least 1 prior immunotherapy and/or chemotherapy regimen for metastatic&#xD;
             disease (first 6 patients only)&#xD;
&#xD;
          -  No known brain metastases unless previously treated with radiotherapy and/or surgery&#xD;
             AND is stable for at least 1 month after treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Absolute lymphocyte count ≥ 500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (transfusions allowed)&#xD;
&#xD;
          -  Hematocrit ≥ 24%&#xD;
&#xD;
          -  No other active bleeding&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 times upper limit of normal (ULN) (unless due to Gilbert's disease)&#xD;
&#xD;
          -  AST and ALT &lt; 3 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
          -  No uncontrolled hypercalcemia&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No uncontrolled bronchospasm&#xD;
&#xD;
          -  No hemoptysis&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  Negative serology for all of the following:&#xD;
&#xD;
               -  HIV-1 and HIV-2&#xD;
&#xD;
               -  HTLV-1 and -2&#xD;
&#xD;
               -  Syphilis&#xD;
&#xD;
          -  Rheumatoid factor &lt; 43 units/μL&#xD;
&#xD;
          -  Anti-nuclear antibody &lt; 11 units/μL&#xD;
&#xD;
          -  No history of multiple sclerosis, systemic lupus erythematosus, or myasthenia gravis&#xD;
&#xD;
          -  No primary or secondary immunodeficiency&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No allergy to seafood or shellfish that would preclude study participation&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active gastrointestinal bleeding&#xD;
&#xD;
          -  No uncontrolled hyperglycemia&#xD;
&#xD;
          -  No other medical or psychiatric condition or social situation that would preclude&#xD;
             study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3-4 months after&#xD;
             study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior immunization with gp100:209-217(210M) peptide&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 2 weeks since prior steroid therapy except replacement steroids or inhaled&#xD;
             steroids&#xD;
&#xD;
          -  No concurrent corticosteroids except replacement steroids&#xD;
&#xD;
          -  No concurrent dexamethasone&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter J. Urba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Cancer Center, Earle A. Chiles Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Cancer Center at Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

